Table 1.
Summary of suicide data from the Integrated Safety Summaries (ISS) of 14 investigational antidepressants including N patients, patient exposure years (PEY), N suicides, and N suicide attempts
| Approval year | Program | Antidepressant | Placebo | N suicides | N suicide attempts | ||||
|---|---|---|---|---|---|---|---|---|---|
| N | PEY | N | PEY | AD | Placebo | AD | Placebo | ||
| 1991 | Sertraline | 2053 | 507.9 | 786 | 209 | 2 | 0 | 9 | 5 |
| 1992 | Paroxetine | 2963 | 1008 | 554 | 72 | 5 | 2 | 40 | 6 |
| 1993 | Venlafaxine | 2181 | 879 | 451 | 100 | 3 | 1 | -- | -- |
| 1994 | Nefazodone | 3496 | 1018 | 875 | 204 | 9 | 0 | 12 | 1 |
| 1996 | Mirtazapine | 2425 | 671.7 | 494 | 71.4 | 8 | 0 | 29 | 3 |
| 1997 | Venlafaxine ER | 705 | 161.6 | 285 | 42.4 | 1 | 0 | -- | -- |
| 1998 | Citalopram | 4168 | 1347.7 | 691 | 150.3 | 8 | 1 | 91 | 10 |
| 1991–1998 totals | 17,991 | 5593.9 | 4136 | 849.1 | 36 | 4 | 181 | 25 | |
| 2002 | Escitalopram | 715 | 99 | 592 | 83 | 0 | 0 | 4 | 0 |
| 2002 | Duloxetine | 2314 | 754 | 723 | -- | 0 | 0 | 7 | 0 |
| 2008 | Desvenlafaxine | 2667 | 1137.2 | 803 | 112.8 | 1 | 0 | 4 | 1 |
| 2010 | Trazodone ER | 202 | 25.9 | 204 | 28.8 | 0 | 0 | 0 | 1 |
| 2011 | Vilazodone | 2177 | 551.5 | 997 | 136.1 | 0 | 1a | 3 | 1 |
| 2013 | Levomilnacipran | 2655 | 899.5 | -- | -- | 0 | 0 | 4 | 0 |
| 2013 | Vortioxetine | 3060 | 406.3 | 1621 | 213.4 | 0 | 0 | 3 | 0 |
| 2002–2013 totals | 13,790 | 3873.4 | 4940 | 574.1 | 1 | 1 | 25 | 3 | |
-- indicates that data was not available
aEvent occurred prior to first dose of treatment